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e read the report by Doi et al. (1) and the accompanying
ditorial by Honda and Fitzgerald (2) with great interest, and we
ongratulate the investigators for analyzing such a large dataset to
nhance our understanding of intravascular ultrasound (IVUS)–
uided stent deployment. The results of their study confirm the
redictive value of post-intervention minimal stent area for mid-
erm stent patency following implantation of paclitaxel-eluting
tents, as has previously been shown in bare-metal stents and
irolimus-eluting stents (3–5). As the investigators allude to in
heir discussion, whereas these data demonstrate a relationship
etween post-paclitaxel-eluting stent minimal stent area and an-
iographic restenosis, it is unlikely that a single minimal stent area
utoff value becomes clinically useful in guiding drug-eluting stent
DES) percutaneous coronary intervention. There are several
otential reasons for this: 1) the diverse presenting clinical syn-
romes and lesion characteristics of the patient population that
etermine the unpredictable robustness of the neointimal response;
) the varying luminal diameter of the stented segment resulting
rom vessel tapering; 3) the inconsistent angiographic and IVUS
efinitions for in-stent restenosis used in the studies (including
50% diameter stenosis at 6 months [3], 9 months [1], or 12
onths [4], and IVUS minimal lumen area 4 mm2 at 8 months
5]), with a distinct lack of clinically more relevant physiologically
efined restenosis; and 4) the differing stent and polymer design as
ell as pharmacokinetics of drugs eluted from the various DES
latforms.
Clearly, interventionalists are cognizant of the aforementioned
omplexities of predicting DES restenosis as well as risk factors for
tent thrombosis in an individual patient. In this context, it is
easonable to ask whether the incremental imaging data provided
y IVUS-guided stent deployment using our current “IVUS
uidelines” is valuable enough to justify its use in the DES era. We
ave shown that, in contrast to bare-metal stents, overexpansion
oes not play an important role in creating neointimal hyperplasia
nd subsequent ischemic end points following sirolimus- and
aclitaxel-eluting stent implantation (6), suggesting that a more
ggressive DES deployment strategy would be desirable, provided
t can be performed safely. Indeed, the ongoing randomizedulticenter AVIO (Angiography Versus IVUS Optimization) trialay shed light on the value of IVUS-guided percutaneous coro-
ary intervention in the DES era using an aggressive IVUS
eployment strategy. This European study is using as target stent
ross-sectional area 70% of the media to media diameter,
easured after initial stent deployment and averaged between the
roximal and distal part of the stent. The investigators have
reviously found these IVUS-guided stent deployment criteria to
e safe and feasible in a single center study (7). Until the results of
hese ongoing investigations are available, interventionalists will
ontinue to individualize IVUS criteria for bare-metal stent and
ES deployment based on patient, lesion, and anticipated stent
haracteristics focusing on adequate strut apposition and stent
xpansion.
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